05.19.17
Dr. Reddy’s Laboratories is installing India’s first FlexFactory, a single-use manufacturing platform by GE Healthcare, to expand biologics production capacity at its facility in Hyderabad, India. The FlexFactory aims to make manufacturing set-up more flexible and efficient, allowing Dr. Reddy’s to expand its biosimilars position.
The new FlexFactory will support the launch of a portfolio of new biosimilar products in the next few years. Dr. Reddy’s will transition from stainless steel to single-use technologies for enhanced flexibility and efficiency in manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured, as the change over time between products can be reduced by 50% or more.
Cartikeya Reddy, head of Biologics at Dr. Reddy’s Laboratories, said, “We are delighted to be working with GE Healthcare to expand our biologics manufacturing footprint. We strongly believe that the FlexFactory platform from GE will enable us to rapidly ramp-up capacity and serve more patients in both emerging markets and highly regulated markets.”
Milind Palsule, Country Manager, South Asia, GE Healthcare Life Sciences, said, “We are pleased to partner with Dr. Reddy’s in their efforts to increase the availability and affordability of biopharmaceuticals globally by bringing single-use, flexible manufacturing capacity to its facility in Hyderabad. India today has one of the fastest growing biopharma sectors in the world and we are keen to support this development and the production capability of Indian pharma players with the latest biopharma technology and know-how.”
The new FlexFactory will support the launch of a portfolio of new biosimilar products in the next few years. Dr. Reddy’s will transition from stainless steel to single-use technologies for enhanced flexibility and efficiency in manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured, as the change over time between products can be reduced by 50% or more.
Cartikeya Reddy, head of Biologics at Dr. Reddy’s Laboratories, said, “We are delighted to be working with GE Healthcare to expand our biologics manufacturing footprint. We strongly believe that the FlexFactory platform from GE will enable us to rapidly ramp-up capacity and serve more patients in both emerging markets and highly regulated markets.”
Milind Palsule, Country Manager, South Asia, GE Healthcare Life Sciences, said, “We are pleased to partner with Dr. Reddy’s in their efforts to increase the availability and affordability of biopharmaceuticals globally by bringing single-use, flexible manufacturing capacity to its facility in Hyderabad. India today has one of the fastest growing biopharma sectors in the world and we are keen to support this development and the production capability of Indian pharma players with the latest biopharma technology and know-how.”
